Contemporary Endocrinology, Год журнала: 2024, Номер unknown, С. 177 - 188
Опубликована: Янв. 1, 2024
Epigenomics, Год журнала: 2024, Номер 16(4), С. 259 - 271
Опубликована: Фев. 1, 2024
miRNAs play a crucial therapeutic role in diseases such as cancer, diabetes and viral infections, with around 1900 identified the human genome. Some have progressed to clinical trials, miRNA mimics inhibitors are pivotal molecules undergoing evaluation. The review delves into various miRNA-associated emphasizing their precision targeting specific genes, modulating disease pathways diagnostic potential. This underscores importance of therapy, foreseeing innovations medicine techniques for diverse diseases. future envisions improved delivery systems addressing challenges like immunogenicity digestion, while comprehensive miRNA-based omics database could guide development tailored antisense miRNAs, further advancing strategies.
Язык: Английский
Процитировано
13
Human Gene Therapy, Год журнала: 2024, Номер 35(17-18), С. 628 - 648
Опубликована: Авг. 16, 2024
MicroRNAs (miRNAs) are crucial regulators of gene expression involved in various pathophysiological processes. Their ability to modulate multiple pathways simultaneously and their involvement numerous diseases make miRNAs attractive tools targets therapeutic development. Significant efforts have been made advance miRNA research the preclinical stage, attracting considerable investment from biopharmaceutical companies. Consequently, an increasing number miRNA-based therapies entered clinical trials for both diagnostic applications across a wide range diseases. While individual can regulate broad array mRNA targets, this also complicates management adverse effects seen trials. Several candidates discontinued due toxicity concerns, underscoring need comprehensive risk assessments therapeutics. Despite no strategies yet received approval regulatory agencies, prominent progress modulation approaches nano-delivery systems last decade, leading development novel safe well-tolerated drug candidates. In review, we present recent advances therapeutics currently or stages treating rare genetic disorders multifactorial common conditions. We address challenges related safety targeted delivery therapies, as well identification most effective
Язык: Английский
Процитировано
10
Advanced Science, Год журнала: 2025, Номер unknown
Опубликована: Янв. 21, 2025
Abstract Recent advancements in microRNAs (miRNAs) research have revealed their key roles both normal physiological processes and pathological conditions, leading to potential applications diagnostics therapeutics. However, the path forward is fraught with several scientific technical challenges. This review article briefly explores milestones of discovery, biogenesis, functions, application for clinical diagnostic therapeutic strategies miRNAs. The challenges future directions are also discussed fully harness capabilities.
Язык: Английский
Процитировано
1
Immunity Inflammation and Disease, Год журнала: 2025, Номер 13(2)
Опубликована: Фев. 1, 2025
ABSTRACT Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by dysregulated immune responses and multi‐organ involvement. Dysregulation of apoptosis, key process for maintaining homeostasis, plays critical role in the pathogenesis SLE. MicroRNAs (miRNAs), small non‐coding RNAs that regulate gene expression, have emerged as important modulators apoptosis cells, influencing balance between tolerance autoimmunity. Objectives This review aims to comprehensively summarize recent advancements understanding roles miRNAs regulation within cells SLE, highlighting their therapeutic potential restoring mitigating progression. Results Aberrant expression specific contributes dysregulation SLE cells. Pro‐apoptotic miRNAs, such miR‐125b miR‐150, are often downregulated, leading enhanced survival autoreactive Conversely, anti‐apoptotic including miR‐21, upregulated, further disrupting delicate cell apoptosis. Dual‐function miR‐155, exhibit context‐dependent based on cellular environments target interactions. promotes persistence development Conclusions play modulating pathways, making them promising targets Restoring pro‐apoptotic could help reinstate reduce tissue damage. Future research should focus elucidating miRNA targetomes, improving delivery systems, addressing off‐target effects fully harness potential.
Язык: Английский
Процитировано
1
Nanoscale Advances, Год журнала: 2024, Номер unknown
Опубликована: Янв. 1, 2024
Despite recent advancements in cancer therapies, challenges such as severe toxic effects, non-selective targeting, resistance to chemotherapy and radiotherapy, recurrence of metastatic tumors persist. Consequently, there has been considerable effort explore innovative anticancer compounds, particularly immunotherapy, which offer the potential for enhanced biosafety efficacy prevention treatment. One avenue exploration involves miRNA-34 (miR-34) family, known its ability inhibit tumorigenesis across various cancers. Dysregulation miR-34 observed several human cancers, it is recognized a tumor suppressor microRNA due synergistic interaction with well-established p53. However, have arisen therapeutic application miR-34a. These include susceptibility degradation by RNase serum, limiting penetrate capillary endothelium reach target cells, well reports immunoreactive adverse reactions. Furthermore, unexpected side effects may occur, accumulation miRNAs healthy tissues interactions serum proteins on nano-vector surfaces, nanoparticle breakdown bloodstream shearing stress, unsuccessful extravasation nanocarriers cells owing interstitial fluid pressure. these challenges, miR-34a remains promising candidate therapy, other members family also shown inhibiting cell proliferation. While
Язык: Английский
Процитировано
6
PLoS ONE, Год журнала: 2025, Номер 20(1), С. e0307420 - e0307420
Опубликована: Янв. 9, 2025
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate the expression level of target genes in cell. Breast cancer is responsible for majority cancer-related deaths among women globally. It has been proven deregulated miRNAs may play an essential role progression breast cancer. shown many cancers, including cancer, aberrant be associated with drug resistance. This study investigated effect let-7b-5p, detected by bioinformatics methods, on Dox resistance through Aurora Kinase B ( AURKB ) gene. In silico analysis using publicly available miRNA expression, GEO datasets revealed let-7b-5p significantly downregulated BC. Further studies potential targets was most negatively correlated and closely Expression via quantitative PCR confirmed upregulated tissue samples. Later, functional conducted MCF-10A, MCF-7, MDA-MB-231 cell lines demonstrated inhibits cells sensitizes them to conclusion, it let-7b-5p/ axis significant disruption this contribute trigger
Язык: Английский
Процитировано
0
Neuroscience, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Neuroscience, Год журнала: 2024, Номер 553, С. 1 - 18
Опубликована: Июнь 27, 2024
Язык: Английский
Процитировано
4
Non-Coding RNA, Год журнала: 2025, Номер 11(1), С. 3 - 3
Опубликована: Янв. 12, 2025
The discovery of the involvement microRNAs (miRNAs) in cystic fibrosis (CF) has generated increasing interest past years, due to their possible employment as a novel class drugs be studied pre-clinical settings therapeutic protocols for fibrosis. In this narrative review article, consider and comparatively evaluate published laboratory information development miRNA-based We miRNAs involved upregulation CFTR, inhibition inflammation and, finally, exhibiting antibacterial activity. suggest that antago-miRNAs ago-miRNAs (miRNA mimics) can proposed validation settings.
Язык: Английский
Процитировано
0
Nucleosides Nucleotides & Nucleic Acids, Год журнала: 2025, Номер unknown, С. 1 - 25
Опубликована: Янв. 13, 2025
The field of biomedical science has witnessed another milestone with the advent RNA-based therapeutics. This review explores three major RNA molecules, namely: messenger (mRNA), interference technology (RNAi), and Antisense Oligonucleotide (ASO), analyses U.S. Food Drug Administration drugs from 14 pharmaceutical companies in terms targeted genes, diseases types, clinical trials status, mode delivery, year production. Many such are clinically approved or pending approval by (FDA) alongside other leading agencies. Regarding diseases, this article emphasizes cancer therapy, genetic viral infections, two categories drug delivery systems include vectors nanoparticles. Despite tremendous progress made, key issues associated these stability, off-target activities payloads, efficiency cellular uptake, innovative need for engineering techniques modifications. transformative potential therapeutics role technologies addressing needs, paving way a new era precision medicine.
Язык: Английский
Процитировано
0